Related references
Note: Only part of the references are listed.Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
Tracing Leukemia Stem Cells and Their Influence on Clinical Course of Adult Acute Myeloid Leukemia
Eman Z. Kandeel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
CD123 bi-specific antibodies in development in AML: What do we know so far?
Michael J. Slade et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S. Haubner et al.
LEUKEMIA (2019)
CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
Anne E. Bras et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse
Katherine D. Cummins et al.
LEUKEMIA & LYMPHOMA (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
Olivia Campagne et al.
CLINICAL CANCER RESEARCH (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Silvia Arcangeli et al.
MOLECULAR THERAPY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.
Norbert Vey et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM
Frank J. Warnders et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
Anke Steinmetz et al.
MABS (2016)
Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
Pierre Hirsch et al.
NATURE COMMUNICATIONS (2016)
The novel structure make LDM effectively remove CD123+AML stem cells in combination with interleukin 3
Yanjun Zhang et al.
CANCER BIOLOGY & THERAPY (2015)
AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells
Dongmei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
CD123 and its potential clinical application in leukemias
Keqiang Liu et al.
LIFE SCIENCES (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML
Jorge E. Cortes et al.
CANCER (2015)
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
Fanny Angelot-Delettre et al.
HAEMATOLOGICA (2015)
Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia
C. Bradbury et al.
LEUKEMIA (2015)
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
Simon Z. He et al.
LEUKEMIA & LYMPHOMA (2015)
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Cytokine release assays: Current practices and future directions
D. Finco et al.
CYTOKINE (2014)
Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
S. J. Busfield et al.
LEUKEMIA (2014)
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
I. Pizzitola et al.
LEUKEMIA (2014)
MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131- epitope expressed by leukemia stem cells
Jeffrey V. Leyton et al.
LEUKEMIA RESEARCH (2014)
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
M. Ryan Corces-Zimmerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies
Vipra Dhir et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration
R. Blake Pepinsky et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
Liqing Jin et al.
CELL STEM CELL (2009)
Identification of genes with abnormal expression changes in acute myeloid leukemia
Derek L. Stirewalt et al.
GENES CHROMOSOMES & CANCER (2008)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
A van Rhenen et al.
CLINICAL CANCER RESEARCH (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis
U Testa et al.
BLOOD (2002)
Growth factor receptor profile of CD34+ cells in AML and B-lineage ALL and in their normal bone marrow counterparts
M De Waele et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
The IgG Fc contains distinct Fc receptor (FcR) binding sites:: The leukocyte receptors FcγRI and FcγRIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A
BD Wines et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
